메뉴 건너뛰기




Volumn 21, Issue 11, 2019, Pages 1402-1411

The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics

(12)  McMurray, John J V a   DeMets, David L b   Inzucchi, Silvio E c   Køber, Lars d   Kosiborod, Mikhail N e   Langkilde, Anna Maria f   Martinez, Felipe A g   Bengtsson, Olof f   Ponikowski, Piotr h   Sabatine, Marc S i   Sjöstrand, Mikaela f   Solomon, Scott D j  


Author keywords

Diabetes; Heart failure; Natriuretic peptides; Pre diabetes; SGLT2 inhibitor

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DAPAGLIFLOZIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; IVABRADINE; MINERALOCORTICOID ANTAGONIST; PLACEBO; SACUBITRIL PLUS VALSARTAN; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; BRAIN NATRIURETIC PEPTIDE; GLUCOSIDE; HEMOGLOBIN A1C PROTEIN, HUMAN; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

EID: 85069834349     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.1548     Document Type: Article
Times cited : (150)

References (38)
  • 4
    • 85032620814 scopus 로고    scopus 로고
    • Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action
    • Packer M, Anker SD, Butler J, Filippatos G, Zannad F. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol 2017;2:1025–1029.
    • (2017) JAMA Cardiol , vol.2 , pp. 1025-1029
    • Packer, M.1    Anker, S.D.2    Butler, J.3    Filippatos, G.4    Zannad, F.5
  • 5
    • 85052558182 scopus 로고    scopus 로고
    • SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
    • Verma S, McMurray JJ. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia 2018;61:2108–2117.
    • (2018) Diabetologia , vol.61 , pp. 2108-2117
    • Verma, S.1    McMurray, J.J.2
  • 6
    • 85054426104 scopus 로고    scopus 로고
    • Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review
    • Zelniker TA, Braunwald E. Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review. J Am Coll Cardiol 2018;72:1845–1855.
    • (2018) J Am Coll Cardiol , vol.72 , pp. 1845-1855
    • Zelniker, T.A.1    Braunwald, E.2
  • 8
    • 85032165629 scopus 로고    scopus 로고
    • Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials
    • Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation 2017;136:1643–1658.
    • (2017) Circulation , vol.136 , pp. 1643-1658
    • Lytvyn, Y.1    Bjornstad, P.2    Udell, J.A.3    Lovshin, J.A.4    Cherney, D.Z.I.5
  • 10
    • 85063211855 scopus 로고    scopus 로고
    • A trial to evaluate the effect of the sodium glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)
    • DAPA-HF Committees and Investigators
    • McMurray JJ, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD; DAPA-HF Committees and Investigators. A trial to evaluate the effect of the sodium glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail 2019;21:665–675.
    • (2019) Eur J Heart Fail , vol.21 , pp. 665-675
    • McMurray, J.J.1    DeMets, D.L.2    Inzucchi, S.E.3    Køber, L.4    Kosiborod, M.N.5    Langkilde, A.M.6    Martinez, F.A.7    Bengtsson, O.8    Ponikowski, P.9    Sabatine, M.S.10    Sjöstrand, M.11    Solomon, S.D.12
  • 20
    • 77956612624 scopus 로고    scopus 로고
    • Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
    • SHIFT Investigators
    • Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875–885.
    • (2010) Lancet , vol.376 , pp. 875-885
    • Swedberg, K.1    Komajda, M.2    Böhm, M.3    Borer, J.S.4    Ford, I.5    Dubost-Brama, A.6    Lerebours, G.7    Tavazzi, L.8
  • 25
    • 85008477713 scopus 로고    scopus 로고
    • Association between hospital penalty status under the hospital readmission reduction program and readmission rates for target and nontarget conditions
    • Desai NR, Ross JS, Kwon JY, Herrin J, Dharmarajan K, Bernheim SM, Krumholz HM, Horwitz LI. Association between hospital penalty status under the hospital readmission reduction program and readmission rates for target and nontarget conditions. JAMA 2016;316:2647–2656.
    • (2016) JAMA , vol.316 , pp. 2647-2656
    • Desai, N.R.1    Ross, J.S.2    Kwon, J.Y.3    Herrin, J.4    Dharmarajan, K.5    Bernheim, S.M.6    Krumholz, H.M.7    Horwitz, L.I.8
  • 27
    • 85025447806 scopus 로고    scopus 로고
    • Prognostic impact of diabetes and prediabetes on survival outcomes in patients with chronic heart failure: a post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial
    • GISSI-HF Investigators
    • Dauriz M, Targher G, Temporelli PL, Lucci D, Gonzini L, Nicolosi GL, Marchioli R, Tognoni G, Latini R, Cosmi F, Tavazzi L, Maggioni AP; GISSI-HF Investigators. Prognostic impact of diabetes and prediabetes on survival outcomes in patients with chronic heart failure: a post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial. J Am Heart Assoc 2017;6:e005156.
    • (2017) J Am Heart Assoc , vol.6
    • Dauriz, M.1    Targher, G.2    Temporelli, P.L.3    Lucci, D.4    Gonzini, L.5    Nicolosi, G.L.6    Marchioli, R.7    Tognoni, G.8    Latini, R.9    Cosmi, F.10    Tavazzi, L.11    Maggioni, A.P.12
  • 28
    • 78650348663 scopus 로고    scopus 로고
    • The cardiorenal anaemia syndrome in systolic heart failure: prevalence, clinical correlates, and long-term survival
    • Scrutinio D, Passantino A, Santoro D, Catanzaro R. The cardiorenal anaemia syndrome in systolic heart failure: prevalence, clinical correlates, and long-term survival. Eur J Heart Fail 2011;13:61–67.
    • (2011) Eur J Heart Fail , vol.13 , pp. 61-67
    • Scrutinio, D.1    Passantino, A.2    Santoro, D.3    Catanzaro, R.4
  • 31
    • 84949538360 scopus 로고    scopus 로고
    • Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial
    • SHIFT Investigators
    • Komajda M, Tavazzi L, Francq BG, Böhm M, Borer JS, Ford I, Swedberg K; SHIFT Investigators. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. Eur J Heart Fail 2015;17:1294–1301.
    • (2015) Eur J Heart Fail , vol.17 , pp. 1294-1301
    • Komajda, M.1    Tavazzi, L.2    Francq, B.G.3    Böhm, M.4    Borer, J.S.5    Ford, I.6    Swedberg, K.7
  • 32
    • 85019366756 scopus 로고    scopus 로고
    • Association between diabetes and 1-year adverse clinical outcomes in a multinational cohort of ambulatory patients with chronic heart failure: results from the ESC-HFA Heart Failure Long-Term Registry
    • ESC-HFA Heart Failure Long-Term Registry
    • Dauriz M, Targher G, Laroche C, Temporelli PL, Ferrari R, Anker S, Coats A, Filippatos G, Crespo-Leiro M, Mebazaa A, Piepoli MF, Maggioni AP, Tavazzi L; ESC-HFA Heart Failure Long-Term Registry. Association between diabetes and 1-year adverse clinical outcomes in a multinational cohort of ambulatory patients with chronic heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. Diabetes Care 2017;40:671–678.
    • (2017) Diabetes Care , vol.40 , pp. 671-678
    • Dauriz, M.1    Targher, G.2    Laroche, C.3    Temporelli, P.L.4    Ferrari, R.5    Anker, S.6    Coats, A.7    Filippatos, G.8    Crespo-Leiro, M.9    Mebazaa, A.10    Piepoli, M.F.11    Maggioni, A.P.12    Tavazzi, L.13
  • 36
    • 84971221555 scopus 로고    scopus 로고
    • Considerably decreased risk of cardiovascular disease with combined reductions in HbA1c, blood pressure and blood lipids in type 2 diabetes: report from the Swedish National Diabetes Register
    • Eeg-Olofsson K, Zethelius B, Gudbjörnsdottir S, Eliasson B, Svensson AM, Cederholm J. Considerably decreased risk of cardiovascular disease with combined reductions in HbA1c, blood pressure and blood lipids in type 2 diabetes: report from the Swedish National Diabetes Register. Diab Vasc Dis Res 2016;13:268–277.
    • (2016) Diab Vasc Dis Res , vol.13 , pp. 268-277
    • Eeg-Olofsson, K.1    Zethelius, B.2    Gudbjörnsdottir, S.3    Eliasson, B.4    Svensson, A.M.5    Cederholm, J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.